Clinical Trial Update: T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial update on T cell receptor immunotherapy targeting NY-ESO-1 in NY-ESO-1 expressing cancers; study is completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Hepatocellular Carcinoma
• Melanoma
• Meningioma
• Non-small Cell Lung Cancer

Drugs mentioned

• T cell receptor immunotherapy targeting NY-ESO-1

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Melanoma, Meningioma | Phase 2 | Status: COMPLETED | Results posted: 2021-03-24